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ABSTRACT
Reduced conditioning intensity has extended the option of allogeneic hematopoietic stem cell transplantation to
patients who cannot tolerate fully myeloablative regimens. However, relapse and graft-versus-host disease (GVHD)
continue to be major causes of morbidity and mortality. We prospectively tested whether a moderate reduction of the
intensity of the preparative regimen would lead to significant reduction in regimen-related toxicity without com-
promising tumor control in a cohort of 44 patients ineligible for conventional hematopoietic stem cell transplanta-
tion. Patients were conditioned with fludarabine, busulfan, mycophenolate, and total lymphoid irradiation. Tacroli-
mus and methotrexate were given as prophylaxis for GVHD. Donors were 5 of 6 or 6 of 6 matched family members.
The median age was 61 years. Eleven patients had comorbid conditions that precluded conventional myeloablative
transplantation. Fatal regimen-related organ toxicity occurred in 3 patients. The cumulative incidence of grade 2 to
4 or grade 3 to 4 acute GVHD by day 100 was 38% (95% confidence interval [CI]  25%, 55%) and 20% (95% CI 
10%, 39%), respectively, with a median time to onset of 66 days. For the entire cohort, 1-year overall survival,
disease-free survival, and relapse rates were 54% (95% CI  41%, 71%), 47% (95% CI  35%, 65%), and 37% (95%
CI  19%, 51%), respectively. Outcomes differed based on stage of disease at time of transplantation, advanced (n 
19) versus nonadvanced (n  25). Median survival times were 138 days and 685 days for subjects with advanced and
nonadvanced disease, respectively (P  .005). After adjusting for age and comorbidity, disease stage continued to be
significantly associated with overall survival (P  .005). In conclusion, a moderate reduction in conditioning dose
intensity resulted in delayed onset of acute GVHD (compared with historical controls). A reduction in conditioning
intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the
conditioning regimen for tumor control.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Highly intense, myeloablative preparative regimens for alloge-
neic stem cell transplantation (SCT) are associated with sub-
stantial regimen-related toxicity, thus limiting use of this treat-
ment strategy to younger patients, generally free of comorbid
conditions other than their underlying hematologic disease. To
extend the option of allogeneic SCT to older patients and/or
those with comorbid conditions, several centers have piloted
preparative regimens of varying intensity based on the observa-
tion that allogeneic lymphocytes can sometimes exert powerful
anti-tumor effects [1-9]. Preparative regimens that dramatically
reduce the intensity of conditioning have been complicated by
high rates of relapse, underscoring the importance of the anti-
tumor component of the preparative regimen [1,6]. Alterna-
tively, in a cohort of young patients with standard-risk malig-
nancies or nonmalignant disorders who would normally be
candidates for conventional transplantation, Slavin et al. found
that a moderate reduction in the intensity of the preparative
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regimen was generally well tolerated and associated with a high
14-month survival rate of 77.5% [4]. We prospectively tested
whether a similar moderate reduction of the intensity of the
preparative regimen would reduce regimen-related toxicity
without compromising tumor control in a cohort of 44 patients
ineligible for conventional allogeneic hematopoietic stem cell
transplantation (HSCT) with generally more advanced disease
states. We modiﬁed the conditioning used by Slavin et al. by
substituting oral mycophenolate (MMF) and a single 200 cGy
fraction of total lymphoid irradiation (TLI) for intravenous
anti-thymocyte globulin (ATG). Although we did not have com-
parative data, we believed that MMF/TLI would provide similar
host immunosuppression to aid engraftment with easier admin-
istration and less toxicity than ATG.
PATIENTS AND METHODS
Eligibility Criteria
The University of Michigan institutional review board ap-
proved this study and all patients gave written informed consent
before enrollment. Between March 1999 and December 2000,
44 patients were prospectively enrolled into the study. Patients
were eligible if they were aged 55 years or older and diagnosed
with any of the following conditions or high-risk factors: acute
myeloid leukemia (AML) not in complete remission; acute lym-
phoblastic leukemia not in complete remission; Philadelphia
chromosome, t(4;11), a presenting white blood cell count
30,000/L, or took longer than 4 weeks to enter CR; chronic
myeloid leukemia (CML) in chronic or accelerated phase; my-
elodysplastic syndrome (MDS) with international prognostic
score of intermediate 1 and higher who were also transfusion-
dependent; chronic lymphocytic leukemia (CLL) who pro-
gressed after ﬁrst-line therapy; or patients with Hodgkin’s or
non-Hodgkin’s lymphoma (NHL) who were not curable with
conventional chemotherapy and did not have any tumor 5 cm
in diameter. Patients younger than 55 years of age were eligible
if they were diagnosed with a hematologic malignancy not cur-
able with conventional chemotherapy and were ineligible for a
conventional myeloablative SCT protocol because of compro-
mised organ function. All patients had an ejection fraction of at
least 30%, FEV1 and FVC of at least 60% of normal, bilirubin
level 2.0, transaminases no greater than 3 times normal for
age, and Karnofsky performance status of at least 60%. All
patients had a willing and healthy related donor who was either
5 of 6 or 6 of 6 HLA-matched by molecular techniques.
Preparative Regimen
The preparative regimen consisted of ﬂudarabine 25 mg/m2
intravenously daily for 5 days (days -11 to -7) followed by
busulfan 0.5 mg/kg orally every 6 hours for 16 doses (days -6 to
–3). MMF 750 mg orally twice per day for actual weight 80 kg
(1000 mg orally twice per day for weight 80 kg) was given
from day -6 to day 0. TLI 2 Gy was given on day 0. For the
calculation of the body surface area, the actual body weight was
used. For the calculations of drug dosages based on body weight,
the mathematic mean of the actual and ideal body weight was
used. Patients with acute leukemia or high-grade lymphoma
received intrathecal cytarabine of 30 mg/m2 before transplanta-
tion. If tumor was seen on examination of the spinal ﬂuid, the
same cytarabine dose was repeated intrathecally every 2 to 3 days
until clearance of tumor and then 1 additional dose was given.
Stem Cell Collection
Donors received granulocyte colony-stimulating factor 16
g/kg divided twice per day for 4 days for stem cell mobiliza-
tion. The target dose was a minimum of 2  106 CD34
cells/kg of recipient weight.
Graft-versus-Host Disease Prophylaxis
Tacrolimus 0.06 mg/kg was given orally twice per day
starting on day -6 until day 56. Dose adjustments were made as
necessary to achieve a target level of 10 to 15 ng/mL. Provided
that the patient was free from graft-versus-host disease
(GVHD), starting on day 57 the tacrolimus dose was tapered by
20% every 4 weeks until it was discontinued on day 180. Meth-
otrexate of 5 mg/m2 was given on days 1, 3, 6, and 11 following
transplantation.
Chimerism Studies
Bone marrow aspirates were obtained monthly for 6 months
following transplantation to assess chimerism by differences in
the variable number of tandem repeats between recipient and
donor.
Definitions of Toxicity, GVHD, and Response
Toxicities were graded using the Bearman scale [10].
GVHD was staged and graded according to the International
Bone Marrow Transplant Registry scale [11].
Patients were evaluated for response starting at day 28.
Patients were evaluated by disease-speciﬁc guidelines. For leu-
kemia, the absence of any histopathological, cytogenetic, or
molecular evidence of disease (by polymerase chain reaction
when applicable) was considered a CR. Persistent disease was
deﬁned as persistent evidence of disease by histopathological,
cytogenetic, or molecular determination. Relapse was deﬁned as
the appearance of leukemia cells in the peripheral blood or
marrow. For lymphomas, CR meant the radiographic (and,
when appropriate, histological) disappearance of all tumor for a
period of 1 month. Partial remission (PR) meant a 50% de-
crease in the sum of the products of the perpendicular diameters
of all measured lesions without any evidence of progression of
any lesion or the appearance of any new lesion for 1 month.
Stable disease meant any change in measurable disease, which is
less than the criteria for PR and without evidence for progres-
sion. Progressive disease was deﬁned as a 50% increase in the
biperpendicular product of any single lesion or the development
of any new lesion. For myeloma, complete response was disap-
pearance of serum M-protein and Bence Jones protein by im-
munoﬁxation and no monoclonal plasma cells in the bone mar-
row. A partial response included 75% reduction in serum
myeloma protein, 95% reduction in Bence Jones protein, and
5% bone marrow plasma cells. Progression was deﬁned as an
increase of 50% in serum myeloma protein over prior measure-
ments that did not resolve within 2 months. All other persistent
myeloma was considered stable disease.
Statistics
CML in chronic phase, refractory anemia, multiple my-
eloma, acute leukemia in CR, and lymphoma in PR or CR were
considered nonadvanced disease for the purposes of analysis.
Untreated refractory anemia with excess blasts with or without
transformation and leukemia or lymphoma in relapse or refrac-
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tory to therapy were considered advanced disease for the pur-
poses of analysis. Rates of overall survival and relapse were
computed with Kaplan-Meier methods, and between-group
comparisons of overall survival and relapse were made with a
log-rank test. Due to the competing risk of death, GVHD rates
were summarized with cumulative incidence rates and corre-
sponding 95% conﬁdence intervals (CIs). A Cox regression
model of overall survival was used to assess the association of
stage with overall survival adjusted for age, presence of renal
comorbidity, and presence of other comorbidity. A similar Cox
regression model was used for rate of relapse. Association of
covariates to best response was assessed with Fisher exact test.
All P values are two-sided.
RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. The
median age was 61 years (range, 29-71 years). Thirty-eight of
the 44 patients were older than 55 years. Thirteen patients
(including 7 patients also eligible by age criteria) had comorbid
conditions that precluded conventional myeloablative transplan-
tation. The 6 patients who were eligible on the basis of comor-
bid conditions alone had a Karnofsky performance status be-
tween 60 and 80 (3), renal failure (1), combined severe restrictive
and obstructive lung disease presumably from CLL (1), and
aspergillus pneumonia still under therapy (1).
Engraftment
The median cell dose transplanted for the 44 patients was
5.4  106 CD34 cells/kg (range, 1.1-29.3  106 CD34
cells/kg). Forty-one of the 44 patients developed severe neutro-
penia (absolute neutrophil count500/L). Three patients died
before engraftment (days 6, 10, and 16 from rapidly progressive
lymphoma, sepsis, and acute respiratory distress syndrome
(ARDS) associated with sepsis, respectively). All remaining pa-
tients achieved a minimum absolute neutrophil count of 500/L
at a median of 12 days. There was no difference in time to
engraftment between those with advanced and nonadvanced
disease.
Chimerism
Donor/recipient chimerism in the marrow was assessed at
day 30 in 38 patients. Patients were not assessed for chimerism
due to early death (4), persistent disease (1), and lack of genetic
polymorphism between the donor and recipient for selected
markers (1). Only 6 patients had evidence of 10% recipient
cells at day 30. Two of these patients relapsed at day 40 and day
98, respectively. One patient with refractory anemia achieved
cytogenetic remission at day 60 and was alive and disease-free 17
months after HSCT. Two patients with CLL had persistent
disease at day 30 that slowly cleared without intervention at 3
and 7 months, respectively. These two patients were alive, dis-
ease-free, and with 100% donor cells at 13 and 17 months after
HSCT, respectively. One patient with persistence of 10%
recipient cells at day 30 was alive with persistent CLL at 13
months after HSCT.
Surveillance marrow examinations detected reappearance of
recipient DNA bands (5%) by variable number of tandem
repeat analysis in 4 cases following prior 100% donor chimer-
ism. In 2 cases, overt clinical relapse occurred 1 month later; in
the other 2 cases, the recipient DNA bands disappeared without
intervention on follow-up examination 1 month later.
Regimen-Related Organ Toxicities
Fatal regimen-related organ toxicity occurred in 3 patients.
One patient with a history of prior renal transplantation died of
sepsis and renal failure on day 10. A second patient died of sepsis
and ARDS on day 16. Congestive heart failure present before
transplantation contributed to the death of another patient of
sepsis and ARDS on day 61. There were no cases of veno-
occlusive disease nor were there any other grade 3 or 4 regimen-
related toxicities. Renal toxicity, generally reversible, was com-
mon. Fourteen of the 44 (32%) patients developed a peak
creatinine level between 1.5 and 1.9 mg/dL and 5 patients (11%)
developed a peak creatinine level 2 mg/dL during the ﬁrst 100
days. In many of these patients, the dose of tacrolimus was
decreased to reduce further renal toxicity. However, there was
no difference in the probability of death or acute GVHD in this
group of patients compared with patients who did not have renal
toxicity. One patient, with pretransplantation renal failure, was
unable to tolerate tacrolimus and died of GVHD on day 181
despite treatment with other non-nephrotoxic immunosuppres-
sive agents.
Infections
Infectious complications in the ﬁrst 100 days were common.
Thirty-one infectious episodes occurred in 23 different patients.
Bacterial infections, accounting for 22 of the 31 infectious epi-
sodes, included 14 positive blood cultures, 3 bacterial urinary
tract infections, 1 case of pneumonia, one case of cellulitis, one
case of salmonella enteritis, and 2 cases of Clostridium difﬁcile
enteritis. Bacterial infections accounted for 2 deaths, both of
vancomycin-resistant enterococcus sepsis in patients with per-
sistent AML. Three fungal infections, all candidal, 2 invasive
and 1 case of thrush also developed in the ﬁrst 100 days. There
were also 2 mycobacterial pneumonias, 1 each of Mycobacterium
kansasii and Mycobacterium tuberculosis diagnosed from bronchial
alveolar lavages. Five viral infections occurred in 4 patients,
which included 1 patient with simultaneous cytomegalovirus
and respiratory syncytial virus pneumonia, 1 patient with cyto-
Table 1. Patient Characteristics (n  44)
Age
Median, 61 y
(range, 29-71 y)
Reason for eligibility
Age > 55 y 31
Age > 55 y and comorbid condition 7
Comorbid condition alone 6
Comorbid conditions
Performance status < 80 5
Renal disease* 3
Lung disease† 2
Congestive heart failure 1
Hemachromatosis 1
Aspergillus pneumonia under treatment 1
*Renal disease consisted of 2 patients with elevated creatinine levels
(1.9 and 2.9) and 1 patient with a prior kidney transplantation.
†Lung disease consisted of 1 patient with emphysema and 1 patient
with both restrictive and obstructive pulmonary disease (presumed from
CLL).
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megalovirus antigenemia, and 2 patients with viral enteritis from
rotavirus infection and adenovirus. Finally, 1 patient died of
presumed sepsis and adult respiratory distress syndrome, but no
organism was identiﬁed.
After day 100, infectious complications were less common,
more often viral or fungal, and generally developed while pa-
tients were under treatment for GVHD. Five bacterial infec-
tions were diagnosed: 3 episodes of bacteremia, including 1
death of sepsis, 1 case of Nocardia pneumonia, and 1 case of
urosepsis. There were 5 cases of invasive aspergillus and 8 cases
of viral infection (4 oropharyngeal herpes simplex, 1 nasopha-
ryngeal rhinovirus, and 3 viral diarrhea: rotavirus, cytomegalo-
virus, and adenovirus).
GVHD
There were 13 cases of signiﬁcant (grades 2 to 4) acute
GVHD: 9 grade 2, 3 grade 3, and 1 grade 4. The patient with
grade 4 GVHD died. GVHD of the skin was the most common
manifestation (11 patients), followed by intestinal GVHD (5
patients), and liver GVHD (2 patients). The cumulative inci-
dence of grade 2 to 4 or grade 3 to 4 acute GVHD by day 100
was 38% (95% CI  25%, 55%) and 20% (95% CI  10%,
39%), respectively, with a median time to onset of 66 days. Two
additional patients developed biologically acute GVHD that
occurred after day 100. In one case, biopsy-proven GVHD of
the intestines and liver developed on day 129 and progressed
rapidly to death on day 148. In another case, a maculopapular
rash characteristic of acute GVHD developed on day 136. The
patient remained alive with chronic GVHD of the mouth, eyes,
and lungs. If the 2 late-onset cases are included, the median time
to onset of grade 2 to 4 GVHD was 75 days and acute GVHD
was the proximate cause of death for 3 patients. Chronic GVHD
occurred in 24 of 33 patients (limited 6 and extensive 18) who
survived to at least day 100. The last occurrence of GVHD was
day 220, at which point the cumulative incidence of chronic
GVHD was 68% (95% CI  54%, 82%). No cases of biolog-
ically chronic GVHD occurred before day 100. The most com-
mon manifestation was skin involvement (18 cases), followed by
oral (16), liver (6), ocular (6), intestinal (3), and pulmonary (3).
Skin and/or mouth involvement was more likely than liver,
ocular, intestinal, or pulmonary involvement (P  .003).
Chronic GVHD was considered the cause of death for 3 pa-
tients. One patient died of opportunistic infection at day 181
while on immunosuppression for GVHD and 2 patients died on
days 347 and 435 from liver and pulmonary GVHD, respec-
tively.
Disease Responses
Patient responses are listed in Table 2 and Table 3. Ten
patients were not evaluable for disease response due to death
before day 28 from nonrelapse cause (3) or continuous CR for
acute leukemia (7). The remaining patients, with disease present
at time of transplantation, were evaluable for response. Fourteen
of 16 patients with MDS, AML, or CML achieved CR by 60
days posttransplantation, including cytogenetic or molecular
remission when assessable. The 2 patients who did not respond
had MDS (refractory anemia with excess blasts in transforma-
tion) were refractory to additional chemotherapy after trans-
plantation, and donor leukocyte infusions (DLIs) were not per-
formed.
Slower times to maximal response were seen for patients
with CLL and multiple myeloma. Three of the four patients
with CLL achieved a CR, but the responses took more than 3
months to achieve. One patient with CLL remained alive, but
never achieved a CR. Three of the 5 patients with multiple
myeloma responded, 1 CR and 2 PR. The other 2 patients have
stable disease, ongoing now for 13 and 18 months, respectively.
Among the responders, the myeloma response was slow to
develop with the maximal decrease in the monoclonal gam-
mopathy occurring 4 to 12 months posttransplantation. Finally,
5 of the 8 patients with NHL responded, 2 CRs and 3 PRs.
The likelihood of achieving a response did not differ be-
tween patients with advanced and nonadvanced stage (P  not
signiﬁcant), but the lack of signiﬁcance may simply reﬂect the
size of the study population or the heterogeneous diseases
treated. A relationship between GVHD and the likelihood of
achieving a response could not be demonstrated, but the size of
the study is not large enough to make any deﬁnitive statements
about GVHD and likelihood of response.
Outcomes
For the entire cohort, with a median follow-up of 24
months, the 1-year overall survival rate was 54% (95% CI 
41%, 71%) (Figure 1). The 1-year disease-free survival and
relapse rates were 47% (95% CI  35%, 65%) and 37% (95%
CI  19%, 51%), respectively. Outcomes differed based on the
presence of advanced (n  19) or nonadvanced (n  25) disease.
Median survival times (Figure 2) were 685 days and 138 days for
subjects with nonadvanced and advanced disease, respectively
(P  .005). After adjusting for age and comorbidity, disease
stage continued to be signiﬁcantly associated with overall sur-
vival (P  .005). Although relapse rates were lower for patients
with nonadvanced disease compared with advanced disease, this
difference was not statistically signiﬁcant even after adjustment
for age and comorbidity. Neither relapse nor survival was asso-
ciated with the occurrence of acute GVHD, but this may be
simply a reﬂection of sample size. Cell dose had no signiﬁcant
relationship with overall survival whether treating cell dose as a
continuous variable or categorizing cell dose into quartiles.
DISCUSSION
Reducing the intensity of preparative regimens to minimize
regimen-related morbidity and mortality has been the focus of
much research over the past few years [1-9]. The intensity of
these regimens range from nonablative [6,7,12] to moderately
ablative [4]. The reduced-intensity regimen used in this study
was moderately ablative and similar to that used by Slavin et al.
in a study of younger, generally healthy patients [4]. Because we
did not observe any primary graft failures, we believe that the
substitution of MMF/TLI for ATG is adequate for the purpose
of preventing rejection. Toxicity from the conditioning regimen
in this study was signiﬁcant, but rarely fatal, and similar to that
seen in other studies of moderately reduced–intensity condition-
ing [1,4,5,8]. Although a direct comparison of these groups is
not possible, we suspect that the overall regimen-related toxicity
we observed is probably less than would be seen in this older and
sicker patient population with a conventional conditioning reg-
imen.
J.E. Levine et al.
192
Marrow Chimerism Did Not Predict Relapse
In the present study, neutrophil engraftment in this study
was prompt. The intensity of the regimen was sufﬁcient to
ensure near-complete donor engraftment in most patients by
day 30. We considered the possibility that the biological signif-
icance of mixed chimerism present after a moderately ablative
regimen such as the one used in this study may be different
compared with fully myeloablative conditioning. In this study, a
small number of patients had low levels of mixed chimerism
(10% recipient cells) at day 30, which was not predictive of
outcome. The level of recipient chimerism increased before
relapse in 3 patients, but in 2 patients reappearance of recipient
DNA did not herald relapse. In myeloablative transplantation,
reappearance or an increasing percentage of recipient DNA can
be predictive of relapse [13-15]. In the present study, analysis for
bone marrow chimerism at day 30 did not predict outcome,
however, this ﬁnding should be interpreted cautiously given the
small numbers of patients involved. Perhaps, in the setting of
reduced conditioning intensity, the presence of mixed chimer-
ism at day 30 may reﬂect an ongoing graft-versus-leukemia
process and remission may yet be achieved. Furthermore, be-
cause the graft-versus-malignancy effect is largely a lymphocyte-
mediated event, perhaps chimerism of donor T cells, which was
not examined here, would prove more informative [6,16].
GVHD Was Common but Delayed in Onset
The incidence of GVHD in this study (38%) is similar to
the 35% to 44% reported in conventional HSCT [17,18] and
other moderately ablative intensity trials [4,6,8]. The median
time to onset of acute GVHD in this study was 66 days com-
pared with 16 to 20 days for conventional HSCT recipients
[17,18], all of whom received tacrolimus for a similar length of
time. Similarly, in an analysis of more than 7000 HLA-identical
sibling non–T-cell-depleted transplantations for early- or inter-
mediate-stage leukemia, all of whom were given cyclosporine
plus methotrexate, 90% of subjects who experienced GVHD
Table 2. Outcomes for Advanced-Stage Patients
Disease
Pre-BMT
Status
Day of Onset
of GVHD
Maximum Acute
GVHD Stage
Chronic
GVHD
Best
Response
Day Best Response
Achieved Outcome
MDS 3 AML 1st relapse — 0  Cytogenetic
remission
29 Relapsed d 91, died d 138
MDS 3 AML Refractory — 0  Cytogenetic
remission
30 Relapsed d 105, died
d 168
AML 1st relapse — 0 NE NE — Died of sepsis d 16
CLL Refractory — 0  NR — Alive with stable disease,
d 394
CLL Refractory — 0  CR 100 Alive in remission, d 336
CLL Refractory 42 2  Cytogenetic
remission
212 Alive in remission, d 493
CMML 1st relapse — 0 NE CR 31 Died of sepsis, d 69
CMML 1st relapse — 0  Cytogenetic
remission
34 Relapsed d 93,
immunosuppression
stopped, developed
GVHD, and now alive
in remission, d 306
NHL* Refractory 73 3 NE PR 65 Died of tuberculosis,
d 101
NHL† Refractory 36 4 NE PR 12 Died of GVHD, d 51
NHL‡ Refractory — NE NE PD — Died of disease, d 6
NHL† Refractory 98 2  CR 177 Alive in remission, d 366
NHL§ Refractory 169 0  CR 29 Died in remission of
acetaminophen
overdose, d 561
RAEB Refractory 75 3  NR — Died of GVHD, d 93
RAEB-T Untreated — NE NE NE — Died of ARDS, d 10
RAEB-T Untreated — 0 NE NR — Died of disease, d 63
RAEB-T Untreated — 0  NR — Died of disease, d 108
RAEB-T Untreated 27 2  Cytogenetic
remission
36 Relapsed d 261, died
d 314
RAEB-T Untreated 90 2  Cytogenetic
remission
34 Died in remission of
pneumoccocus, d 336
BMT indicates bone marrow transplantation; MDS 3 AML, myelodysplastic syndrome transformed into acute myeloid leukemia; RAEB-T,
refractory anemia with excess blasts in transformation; NE, not evaluable; NR, no response; PD, progressive disease.
*Cutaneous T-cell lymphoma.
†Mantle cell lymphoma.
‡Cutaneous B-cell lymphoma with central nervous system metastases.
§Follicular, mixed NHL.
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did so by day 60 (personal communication, Mary Horowitz,
MD, International Bone Marrow Transplant Registry, June 6,
2002), compared with less than half of the patients in the present
study. The delay in onset of acute GVHD in reduced-intensity
transplantation suggests that perhaps time of onset should no
longer be part of the deﬁnition of acute or chronic GVHD. We
can not rule out the possibilities that differences in GVHD
prophylaxis or the generally older patient population may ac-
count for the later onset of GVHD in this study, but we think
that those are not likely explanations. The main difference
Table 3. Outcomes for Patients with Nonadvanced Disease
Disease
Pre-BMT
Status*
Day of Onset
of GVHD
Maximum Acute
GVHD Stage
Chronic
GVHD
Best
Response
Day Best
Response
Achieved Outcome
ALL CR1 21 2  CCR 27 Relapsed d 174, died
d 207
ALL-Ph CR1 143 0  CCR 31 Alive in remission, d 486
CMML 3 AML CR1 — 0  CCR 30 Relapsed d 98, died
d 128
MDS 3 AML CR1 23 1 NE NE — Died from sepsis d 26
MDS 3 AML CR1 — 0  CCR 29 Alive in remission, d 210
MDS 3 AML 8, 11 98 0  Cytogenetic
remission
29 Alive in remission, d 638
AML CR1 210 0  CCR 30 Relapsed d 336, died
d 414
AML CR2 — 0  CCR 30 Relapsed d 122, died
d 179
AML CR2 177 0  CCR 31 Alive in remission, d 408
CLL PR 85 2  CR 116 Alive in remission, d 471
CML CP 93 1  Molecular
remission
58 Alive in remission, d 770
CML CP 136 0  Molecular
remission
29 Alive in remission, d 587
MM 3B 76 2  CR 136 Alive in remission, d 874
MM 3A 122 0  NR — Alive with stable
disease, d 554
MM 3B — 0  NR — Alive with stable
disease, d 409
MM 3A 220 0  PR 364 Died of GVHD d 435
MM 3A 112 0  PR 211 Alive in partial
remission, d 462
NHL† PR 18 2 NE NR — Relapsed d 59, died d 61
NHL‡ PR 23 1  PR 110 Alive in partial
remission, d 486
NHL§ PR 60 3  Mixed
response
29 Relapsed d 145,
immunosuppression
stopped, died of
GVHD d 181
RA 8 200 0  Cytogenetic
remission
31 Alive in remission, d 773
RA Complex — 0  Cytogenetic
remission
62 Alive in remission, d 351
RA 5q-, 13q- 129 0  Cytogenetic
remission
35 Died of GVHD d 148
RA 5q-, der11 197 0  Cytogenetic
remission
61 Alive in remission, d 252
RAEB-T 5, 7, der11 92 2  CR 31 Alive in remission, d 322
ALL indicates acute lymphoblastic leukemia; ALL-Ph, acute lymphoblastic leukemia, Philadelphia chromosome–positive; CMML 3 AML,
chronic myelomonocytic leukemia transformed into acute myeloid leukemia; MM, multiple myeloma; RA, refractory anemia; CR1, ﬁrst complete
remission; CR2, second complete remission; CP, chronic phase; CCR, continuous complete remission; NR, no response.
*If the patient was in morphological remission but cytogenetic evidence of persistent disease was present at BMT, the cytogenetic abnormalities
are noted.
†Lymphoblastic lymphoma.
‡Mantle cell lymphoma.
§Monocytoid B-cell lymphoma.
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between this study and the earlier onset of GVHD observed in
other studies using tacrolimus or cyclosporine to prevent
GVHD in the context of related donor transplantation is the
intensity of the conditioning regimen. We know that cytokine
release from tissue damage is critical in the pathogenesis of GVHD
[19], and it is possible that a reduction in conditioning intensity
results in less cytokine release. This hypothesis needs to be con-
ﬁrmed by laboratory testing.
Figure 1. Kaplan-Meier plot of overall survival (solid line) with 95% conﬁdence limits (dashed lines) for all patients (N  44).
Figure 2. Kaplan-Meier plot of overall survival for patients with advanced-stage disease (n 19, solid line) and patients with non-advanced disease
(n  25, dashed line).
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Reduced-Intensity Conditioning Did Not Cure Most
Patients with Advanced-Stage Disease
In this study, durable progression-free survival was not
achieved for most patients with advanced-stage disease, even
when disease responses were achieved early after transplanta-
tion. For example, patients with leukemia or MDS were likely to
be in remission at day 30. But remission duration was much
shorter for patients with advanced-stage disease compared with
nonadvanced disease. Median follow-up is 24 months and more
relapses may yet occur. For patients with advanced-stage dis-
ease, treatment-related toxicity and GVHD also contributed to
the high mortality rate. Our ﬁnding that pretransplantation
disease stage is prognostically important is consistent with a
retrospective analysis of 92 patients treated with a variety of
reduced-intensity regimens [20]. In that study, with a median
follow-up of 8 months, multivariate analysis found that patients
with advanced-stage disease were more than twice as likely to die
as patients with nonadvanced stage disease. Thus, although
allogeneic HSCT can be offered to older and sicker patients, the
beneﬁt of this approach for such patients with advanced-stage
disease is yet to be established. Reducing treatment-related
morbidity and mortality is desirable, but further reduction in
conditioning intensity without other measures to control cancer
is unlikely to result in long-term disease control for patients with
advanced-stage disease. Because relapse is also a major cause of
poor outcome for patients who undergo intensive conditioning,
it is not realistic to expect fewer relapses with reduced-intensity
conditioning unless other mechanisms of enhancing an anti-
tumor effect are developed. Strategies that protect against reg-
imen-related toxicity, such as amifostine [21], may permit more
intense regimens for this group of patients. Another approach is
the use of DLIs to prevent relapse. In a report of 21 patients
with refractory hematologic malignancies, Spitzer et al. ob-
served complete responses in 5 of 9 patients (56%) who received
prophylactic DLI compared with only 3 of 11 patients (27%) of
those who did not receive prophylactic DLI [22]. In this rela-
tively young group of patients, acute GVHD developed in 5 of
9 (56%) patients who received a prophylactic DLI, highlighting
the potential toxicity such an approach may have in an older, less
healthy population. Clearly, strategies to preserve the graft ver-
sus leukemia (GVL) effect while protecting against GVHD are
needed. If the delayed onset of GVHD observed in this study
reﬂects reduced cytokine release from tissue damage, then
strategies that protect against inﬂammatory cytokines may
prove to be useful. Experimental models of keratinocyte
growth factor as a cytokine shield or blockade of lipopoly-
saccharide, an important mediator of cytokine release, have
shown protection against GVHD while preserving GVL
[23,24]. In this study, the potential advantages of reduced-
intensity conditioning in decreasing regimen-related mortal-
ity for older, sicker patients with advanced-stage malignan-
cies were offset by the high rates of relapse and other
complications. By comparison, the patients with nonadvanced
disease, who would not otherwise have been eligible for
allogeneic transplantation, fared relatively well. The success-
ful development of strategies to enhance cancer control, such
as adoptive immunotherapy combined with agents that pro-
tect against GVHD while preserving GVL, will permit this
approach to be extended to higher-risk patients.
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